Annexon Inc at JPMorgan Healthcare Conference Transcript
All righty. Let's go ahead and get started. Welcome everybody, to the Wednesday morning of the 41st Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analyst here at JPMorgan. I'm joined by Malcolm [Cunha] and Priyanka Grover from the team. Our first presenting company of today is Annexon. And speaking on behalf of the company, we have CEO, Doug Love. Doug?
Thank you, Anupam and JPMorgan. And thank all of you for joining us this morning. We're super excited to be here to talk about the robust complement pipeline that we have, targeting C1q in the classical pathway. We'll be making forward-looking statements this morning, and invite you to look at our materials on file.
So turning to our mission and who Annexon is, Annexon, frankly, is seeking to thrive by changing the lives of patients. We are focused on giving patients with complement-mediated disease, their lives back, by stopping or preventing them from being robbed of their
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |